- InterView
- On how Eisa’s intrapreneur ‘HeLpy’ is ‘happy’
- by Eo, Yun-Ho Feb 27, 2020 06:35am
- Lately, companies emphasize a notion of internal entrepreneurship, also known as ‘intrapreneurship.’ For companies, innovation is not an option anymore. And this is the time when intrapreneurship becomes the source of internal innovation. So these days, ‘internal venture’ is popular among companies. Without massive investment, an in
- InterView
- I'm happy to introduce Spinraza to patients.
- by Eo, Yun-Ho Feb 21, 2020 06:36am
- Biogen, a bioventure company in the US and a smaller company in Korea. Last year, Biogen Korea, which has about 10 employees, registered and launched insurance benefits for its famous spinal muscular atrophy (SMA) treatment Spinraza (Nusinersen). Prior to listing, Biogen Korea's employees had only five employees. Spinraza, a high-priced
- InterView
- 27 years in the HIRA, feeling worthwhile in public service
- by Lee, Hye-Kyung Feb 3, 2020 06:20am
- There is a problem that the HIRA and the NHIS, which have completed the relocation to Wonju Innovation City, are worried. It is about recruiting professional personnel such as doctors and pharmacists. In particular, The number of pharmacist recruitment is 72 of the HIRA and 35 people in the NHIS, but both institutions cannot failed to fill th
- InterView
- “Changing the public’s view on psoriasis patients”
- by An, Kyung-Jin Jan 22, 2020 06:27am
- “Too many people had no or wrong idea about psoriasis. We opened the crowd funding to raise awareness of psoriasis and to improve the public’s perception on the disease.” A university student-centered crowd funding union, ‘Wishtree’ opened a new funding project this month. The project aims to help patients with psoriasis. Althou
- InterView
- “Why it took 20 years for new flu drug Xofluza to be out”
- by Eo, Yun-Ho Jan 16, 2020 03:07pm
- Since the 2009 flu pandemic, Tamiflu became a prescription drug with household name like Viagra. Tamiflu (oseltamivir) is a good drug. It shifted the world’s paradigm on influenza management and became the symbol of neuraminidase inhibitor drug. However, the unmet medical needs still exist in the market. Antiviral agent can always d
- InterView
- “Key to healthcare innovation is pharmaceutical industry"
- by Kim, Jung-Ju Jan 2, 2020 06:08am
- Korea’s Ministry of Health and Welfare (MOHW) has stated two core goals of the current administration are ‘creating an inclusive welfare state’ and ‘supporting innovative growth of emerging industry.’ The key is definitely the pharmaceutical industry. During a question and answer session with correspondents, Park Min-soo, a direc
- InterView
- Restriction on high dose of Xeljanz
- by Nho, Byung Chul Dec 26, 2019 10:15am
- Recently, the US FDA and the European Medicines Agency (EMA) have restricted the prescription of high doses of Pfizer JAK inhibitor Xeljanz (Tofacitinib citrate). The U.S. FDA changed its permits from primary to secondary for ulcerative colitis, one of the indications for Xeljanz, in July. The EMA has a high risk of thrombotic ulcerative
- InterView
- The key to drug development is not just safety and efficacy
- by Jung, Hye-Jin Dec 5, 2019 06:12am
- “In short, it is an area that is easy to miss even though it is important enough to be the core of new drug development. Most of the domestic companies that have applied for a permit with the US FDA or the European EMA are asked to submit additional data. As more and more pharmaceutical companies are attempting to penetrate overseas, Korean
- InterView
- “Independent Galderma aims for both innovation and jobs”
- by Eo, Yun-Ho Dec 4, 2019 06:43am
- Global pharmaceutical companies are flexible with corporate merger and business acquisition. They are not afraid to take a better choice to survive and advance forward in ever-changing trend. Although such drastic changes cause restructure, downsizing and other issues, global companies have constantly taken the path of changes so far.
- InterView
- “Number one in Asia is what we are shooting for”
- by Kim, Jin-Gu Nov 26, 2019 07:15am
- “As far as dermatological treatment business goes, I think we have a shot at becoming the number one in Asian market”, Cho Yong-joon, CEO at Dongkoo Bio & Pharma (“Dongkoo”) commented. The CEO said ‘entering global market’ is the next long-term goal for the company while it gets closer to its 50th anniversary next year. CEO Cho was
